AU2018228719B2 - Tandem diabody for CD16A-directed NK-cell engagement - Google Patents

Tandem diabody for CD16A-directed NK-cell engagement Download PDF

Info

Publication number
AU2018228719B2
AU2018228719B2 AU2018228719A AU2018228719A AU2018228719B2 AU 2018228719 B2 AU2018228719 B2 AU 2018228719B2 AU 2018228719 A AU2018228719 A AU 2018228719A AU 2018228719 A AU2018228719 A AU 2018228719A AU 2018228719 B2 AU2018228719 B2 AU 2018228719B2
Authority
AU
Australia
Prior art keywords
cd16a
antigen
amino acid
cell
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018228719A
Other languages
English (en)
Other versions
AU2018228719A1 (en
Inventor
Kristina Ellwanger
Ivica FUCEK
Stefan Knackmuss
Erich Rajkovic
Uwe Reusch
Thorsten Ross
Martin Treder
Michael WEICHEL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affimed GmbH
Original Assignee
Affimed GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed GmbH filed Critical Affimed GmbH
Publication of AU2018228719A1 publication Critical patent/AU2018228719A1/en
Application granted granted Critical
Publication of AU2018228719B2 publication Critical patent/AU2018228719B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2018228719A 2017-02-28 2018-02-28 Tandem diabody for CD16A-directed NK-cell engagement Active AU2018228719B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17158566 2017-02-28
EP17158566.4 2017-02-28
EP17174407 2017-06-02
EP17174407.1 2017-06-02
PCT/EP2018/054989 WO2018158349A1 (en) 2017-02-28 2018-02-28 Tandem diabody for cd16a-directed nk-cell engagement

Publications (2)

Publication Number Publication Date
AU2018228719A1 AU2018228719A1 (en) 2019-08-08
AU2018228719B2 true AU2018228719B2 (en) 2023-03-30

Family

ID=61569251

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018228719A Active AU2018228719B2 (en) 2017-02-28 2018-02-28 Tandem diabody for CD16A-directed NK-cell engagement

Country Status (8)

Country Link
US (2) US11180558B2 (enExample)
EP (1) EP3589655B1 (enExample)
JP (1) JP7115758B2 (enExample)
CN (1) CN110382539B (enExample)
AU (1) AU2018228719B2 (enExample)
CA (1) CA3051062C (enExample)
DK (1) DK3589655T3 (enExample)
WO (1) WO2018158349A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143436A (ko) 2018-04-13 2020-12-23 아피메트 게엠베하 Nk 세포 결합 항체 융합 구조체
AU2021357841A1 (en) * 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
CR20230229A (es) * 2020-11-06 2023-09-05 Amgen Res Munich Gmbh Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
WO2022161314A1 (zh) * 2021-01-27 2022-08-04 信达生物制药(苏州)有限公司 针对cd16a的单域抗体及其用途
CN117580865A (zh) * 2021-06-29 2024-02-20 山东先声生物制药有限公司 Cd16抗体及其应用
WO2023079493A1 (en) * 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
EP4426439A1 (en) * 2021-11-03 2024-09-11 Affimed GmbH Bispecific cd16a binders
CN114262382B (zh) * 2021-12-20 2023-09-19 上海恩凯细胞技术有限公司 双特异性抗体及其应用
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN115960234B (zh) * 2022-10-27 2023-12-29 合肥天港免疫药物有限公司 抗cd16a的抗体及其应用
WO2024131731A1 (zh) 2022-12-19 2024-06-27 和铂医药(上海)有限责任公司 "κ/λ"Fab-Fab串联多特异性结合蛋白及其制备和应用
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
DE60127143T2 (de) * 2001-11-14 2007-11-15 Affimed Therapeutics Ag Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
KR101799337B1 (ko) * 2007-06-21 2017-12-20 마크로제닉스, 인크. 공유결합형 디아바디 및 이것의 사용
SI2406284T1 (sl) 2009-03-10 2017-01-31 Biogen Ma Inc. Anti-bcma protitelesa
US20110206672A1 (en) * 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
PT2361936T (pt) * 2010-02-25 2016-07-15 Affimed Gmbh Molécula que se liga a antigénio e utilizações desta
US20140105915A1 (en) 2011-05-27 2014-04-17 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
CN103687879B (zh) * 2011-07-22 2016-05-04 阿菲姆德农业医药公司 多价抗原结合fv分子
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
CA2889764C (en) 2012-11-01 2023-10-10 Martin Lipp An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
JP2016507523A (ja) 2013-02-05 2016-03-10 エンクマフ アーゲー ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
SI3030581T1 (sl) * 2013-08-07 2021-07-30 Affimed Gmbh Mesta za vezavo na protitelo, ki so specifična za EGFRVIII
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
RS59489B1 (sr) * 2015-05-04 2019-12-31 Affimed Gmbh Kombinacija anti-cd30xcd16a antitela sa antagonističkim anti-pd-1 antitelom za terapiju
CN105367660B (zh) * 2015-12-22 2018-12-21 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GANTKE T. ET AL: "AFM26 - Targeting BCMA for NK cell-mediated immunotherapy of multiple myeloma", 12 December 2017 (2017-12-12), XP002779399, Retrieved from the Internet [retrieved on 20180321] *

Also Published As

Publication number Publication date
DK3589655T3 (da) 2022-11-28
AU2018228719A1 (en) 2019-08-08
US20190345249A1 (en) 2019-11-14
JP2020510659A (ja) 2020-04-09
US20220041717A1 (en) 2022-02-10
WO2018158349A1 (en) 2018-09-07
US12264198B2 (en) 2025-04-01
CN110382539A (zh) 2019-10-25
JP7115758B2 (ja) 2022-08-09
US11180558B2 (en) 2021-11-23
CA3051062A1 (en) 2018-09-07
EP3589655A1 (en) 2020-01-08
CN110382539B (zh) 2023-08-08
CA3051062C (en) 2023-09-26
EP3589655B1 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
US12264198B2 (en) Tandem diabody for CD16A-directed NK-cell engagement
US20240294647A1 (en) Uses of nk cell engaging antibody fusion constructs for treatments
US10233258B2 (en) Bispecific binding proteins that bind CD40 and mesothelin
KR102838691B1 (ko) 이중특이적 체크포인트 억제제 항체
JP2023051968A (ja) 多重特異的ＮＫｐ４６結合タンパク質
US10982006B2 (en) Heterodimeric antibodies that bind fibroblast activation protein
CN119365490A (zh) 结合pd-l1、pd-l2和/或cd28的抗体
US20190322767A1 (en) Heterodimeric antigen binding proteins
JP2024521701A (ja) 抗ｃｄ１３７抗体及びその使用方法
RU2774711C2 (ru) Слитые конструкции антител для вовлечения nk-клеток
US20240209113A1 (en) Anti-gpc3 and anti-cd137 multispecific antibodies and methods of use
CA3210650A1 (en) Bispecific antibodies enhancing cell mediated immune responses
HK40034204B (en) Nk cell engaging antibody fusion constructs
HK40034204A (en) Nk cell engaging antibody fusion constructs

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)